Logotype for Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) investor relations material

Regeneron Pharmaceuticals Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Regeneron Pharmaceuticals Inc
Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum summary24 Sep, 2025

Commercial performance and product updates

  • EYLEA HD saw strong sequential demand growth in Q1 and Q2, driven by effective commercial execution and education efforts targeting both physicians and patients.

  • Key upcoming regulatory milestones include a PDUFA date in late October for the prefilled syringe and another in late November for RVO and Q4 dosing sBLA, with confidence in timely resolution of manufacturing issues.

  • Biosimilar competition for EYLEA 2mg has led to gradual market uptake, with additional entrants expected in late 2026, potentially increasing pricing pressure.

  • DUPIXENT continues to perform strongly across eight approved indications, with growth driven by established and new launches, particularly in COPD.

  • Investments in COPD launch leverage existing pulmonary field teams, with high early adoption among top pulmonologists and a focus on both physician and patient education.

Pipeline and R&D strategy

  • Strategic ambition is to develop a basket of opportunities, including longer-acting DUPIXENTs and novel inflammatory targets, to sustain growth beyond DUPIXENT’s exclusivity in 2031.

  • Oncology pipeline features recent approvals for bispecifics, with early Linezyth launch feedback positive and plans to expand into earlier lines and precursor conditions.

  • Upcoming studies include combinations in second line plus myeloma and trials in newly diagnosed and smoldering myeloma, with promising early data in precursor conditions.

  • LAG-3 combination trials in melanoma aim to outperform current standards, with key readouts expected and a head-to-head study against Opdualag maturing by 2027.

  • Complement and Factor XI programs show promise in MG, PNH, geographic atrophy, and anticoagulation, with multiple phase 2 and 3 studies underway and initial data expected in 2027.

Obesity and metabolic programs

  • Muscle-sparing agents combined with GLP-1 therapies demonstrated significant preservation of lean mass during weight loss, with ongoing studies to assess long-term effects.

  • Licensed GLP-1/GIP asset olorepatide will be developed as a monotherapy and in combination, with a phase 3 program planned for next year.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Regeneron Pharmaceuticals earnings date

Logotype for Regeneron Pharmaceuticals Inc
Q3 202528 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Regeneron Pharmaceuticals earnings date

Logotype for Regeneron Pharmaceuticals Inc
Q3 202528 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Regeneron Pharmaceuticals Inc is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company has a pipeline of product candidates comprising multiple therapeutic candidates in Phase I and Phase II clinical studies for the treatment of cancer, wet age-related macular degeneration and diabetic macular edema, atopic dermatitis, asthma, pain, and monoclonal antibodies.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage